Clinical Trial Update: Efficacy and Safety Study of BDB-001 Injection in Patients With Moderate to Severe Hidradenitis Suppurativa (HS) [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of BDB-001 injection in adults with moderate to severe hidradenitis suppurativa has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hidradenitis Suppurativa

Drugs mentioned

• BDB-001

Snippet

Sponsor: Staidson (Beijing) Biopharmaceuticals Co., Ltd | Conditions: Hidradenitis Suppurativa | Phase 2 | Status: COMPLETED